Age related macular degeneration 1
diseaseOn this page
Also known as age related macular degeneration type 1ARMD1macular degeneration, age-relatedmacular degeneration, age-related, 1macular degeneration, age-related, reduced risk ofmacular Degeneration, age-related, type 1
Summary
Age related macular degeneration 1 (MONDO:0011285) is a disease with 5 cohort genes and 14 clinical trials. Top therapeutic interventions include faricimab, metformin, and pegcetacoplan.
At a glance
- Cohort genes: 5
- ClinVar variants: 498
- Clinical trials: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | age related macular degeneration 1 |
| Mondo ID | MONDO:0011285 |
| MeSH | C566411 |
| OMIM | 603075 |
| DOID | DOID:0110014 |
| UMLS | C1864205 |
| MedGen | 400475 |
| GARD | 0024788 |
| Is cancer (heuristic) | no |
Also known as: age related macular degeneration type 1 · ARMD1 · macular degeneration, age-related · macular degeneration, age-related, 1 · macular degeneration, age-related, reduced risk of · macular Degeneration, age-related, type 1
Data availability: 498 ClinVar variants · 5 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal degeneration › macular degeneration › degeneration of macula and posterior pole › age-related macular degeneration › age related macular degeneration 1
Related subtypes (14): wet macular degeneration, age related macular degeneration 2, macular degeneration, age-related, 3, age related macular degeneration 7, age related macular degeneration 4, age related macular degeneration 9, age related macular degeneration 10, age related macular degeneration 11, age related macular degeneration 6, age related macular degeneration 8, age related macular degeneration 12, age related macular degeneration 14, macular dystrophy with central cone involvement, dry age related macular degeneration
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
498 retrieved; paginated sample, class counts are floors:
255 uncertain significance, 102 conflicting classifications of pathogenicity, 60 benign, 47 benign/likely benign, 32 likely benign, 1 pathogenic/likely pathogenic, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 17880 | NM_000041.4(APOE):c.127C>T (p.Arg43Cys) | APOE | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 217863 | NM_031935.3(HMCN1):c.4163del (p.Pro1388fs) | HMCN1 | Pathogenic | no assertion criteria provided |
| 440842 | NM_000041.4(APOE):c.91G>A (p.Glu31Lys) | APOE | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1678086 | NM_002113.3(CFHR1):c.19del (p.Ser6_Val7insTer) | CFHR1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1979364 | NM_031935.3(HMCN1):c.11743G>A (p.Val3915Ile) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 2205 | NM_031935.3(HMCN1):c.16034A>G (p.Gln5345Arg) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294097 | NM_031935.3(HMCN1):c.602A>G (p.Asp201Gly) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294103 | NM_031935.3(HMCN1):c.959G>A (p.Arg320Gln) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294104 | NM_031935.3(HMCN1):c.1021+8T>C | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294107 | NM_031935.3(HMCN1):c.1338G>A (p.Pro446=) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294114 | NM_031935.3(HMCN1):c.2098+12C>A | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294116 | NM_031935.3(HMCN1):c.2119G>T (p.Val707Phe) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294122 | NM_031935.3(HMCN1):c.2385C>T (p.Phe795=) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294127 | NM_031935.3(HMCN1):c.3048+12A>G | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294134 | NM_031935.3(HMCN1):c.3684C>T (p.Ile1228=) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294137 | NM_031935.3(HMCN1):c.3764C>T (p.Thr1255Met) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294139 | NM_031935.3(HMCN1):c.4029A>G (p.Glu1343=) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294150 | NM_031935.3(HMCN1):c.4499A>G (p.Asn1500Ser) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294157 | NM_031935.3(HMCN1):c.4910-14A>G | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294158 | NM_031935.3(HMCN1):c.4920G>A (p.Met1640Ile) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294161 | NM_031935.3(HMCN1):c.5669T>C (p.Leu1890Ser) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294162 | NM_031935.3(HMCN1):c.5706C>T (p.Asn1902=) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294164 | NM_031935.3(HMCN1):c.5852-12T>G | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294173 | NM_031935.3(HMCN1):c.6435G>A (p.Leu2145=) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294179 | NM_031935.3(HMCN1):c.7017A>G (p.Val2339=) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294189 | NM_031935.3(HMCN1):c.7589C>G (p.Ser2530Cys) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294196 | NM_031935.3(HMCN1):c.8241A>G (p.Ala2747=) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294198 | NM_031935.3(HMCN1):c.8485+14C>T | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294205 | NM_031935.3(HMCN1):c.9047-12A>G | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 294206 | NM_031935.3(HMCN1):c.9057T>A (p.Thr3019=) | HMCN1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 8 · Orphanet: 8 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| CFHR1 | Limited | Unknown | age related macular degeneration 1 | 4 |
| HMCN1 | Limited | Autosomal dominant | age related macular degeneration 1 | 4 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| CFHR1 | Orphanet:329931 | C3 glomerulonephritis |
| CFHR1 | Orphanet:93571 | Dense deposit disease |
| CFHR3 | Orphanet:329931 | C3 glomerulonephritis |
| FBLN5 | Orphanet:280598 | Hereditary sensorimotor neuropathy with hyperelastic skin |
| FBLN5 | Orphanet:90348 | Autosomal dominant cutis laxa |
| FBLN5 | Orphanet:90349 | Autosomal recessive cutis laxa type 1 |
| APOE | Orphanet:329481 | Lipoprotein glomerulopathy |
| APOE | Orphanet:412 | Dysbetalipoproteinemia |
Cohort genes → proteins
5 cohort genes, 5 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 5 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| HMCN1 | HGNC:19194 | ENSG00000143341 | Q96RW7 | Hemicentin-1 | gencc,clinvar |
| CFHR1 | HGNC:4888 | ENSG00000244414 | Q03591 | Complement factor H-related protein 1 | gencc,clinvar |
| CFHR3 | HGNC:16980 | ENSG00000116785 | Q02985 | Complement factor H-related protein 3 | clinvar |
| FBLN5 | HGNC:3602 | ENSG00000140092 | Q9UBX5 | Fibulin-5 | clinvar |
| APOE | HGNC:613 | ENSG00000130203 | P02649 | Apolipoprotein E | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| HMCN1 | Hemicentin-1 | Involved in transforming growth factor beta-mediated rearrangement of the podocyte cytoskeleton which includes reduction of F-actin fibers and broadening, flattening and elongation of podocytes. |
| CFHR1 | Complement factor H-related protein 1 | Involved in complement regulation. |
| CFHR3 | Complement factor H-related protein 3 | Might be involved in complement regulation. |
| FBLN5 | Fibulin-5 | Essential for elastic fiber formation, is involved in the assembly of continuous elastin (ELN) polymer and promotes the interaction of microfibrils and ELN. |
| APOE | Apolipoprotein E | APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids. |
Protein-family classification
Druggable: 3 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.6
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Complement | 2 | 107.2× | 4e-04 |
| Antibody/Immunoglobulin | 1 | 5.8× | 0.240 |
| Other/Unknown | 2 | 0.7× | 0.877 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| HMCN1 | Antibody/Immunoglobulin | yes | EGF-type_Asp/Asn_hydroxyl_site, EGF, TSP1_rpt | |
| CFHR1 | Complement | yes | Sushi_SCR_CCP_dom, Sushi/SCR/CCP_sf, ComplSys_Reg/VirEntry_Med | |
| CFHR3 | Complement | yes | Sushi_SCR_CCP_dom, Sushi/SCR/CCP_sf, ComplSys_Reg/VirEntry_Med | |
| FBLN5 | Other/Unknown | no | EGF-type_Asp/Asn_hydroxyl_site, EGF, EGF-like_Ca-bd_dom | |
| APOE | Other/Unknown | no | ApoA_E, Apolipoprotein_A1/A4/E |
Expression context
Cohort genes with no expression data: 0.
5 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 5 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| ascending aorta | 2 |
| descending thoracic aorta | 2 |
| thoracic aorta | 2 |
| liver | 2 |
| male germ line stem cell (sensu Vertebrata) in testis | 2 |
| right lobe of liver | 2 |
| left adrenal gland | 1 |
| left adrenal gland cortex | 1 |
| right adrenal gland cortex | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| HMCN1 | 211 | ubiquitous | marker | descending thoracic aorta, thoracic aorta, ascending aorta |
| CFHR1 | 125 | marker | right lobe of liver, liver, male germ line stem cell (sensu Vertebrata) in testis | |
| CFHR3 | 127 | tissue_specific | marker | right lobe of liver, liver, male germ line stem cell (sensu Vertebrata) in testis |
| FBLN5 | 261 | ubiquitous | marker | thoracic aorta, ascending aorta, descending thoracic aorta |
| APOE | 267 | ubiquitous | marker | left adrenal gland, left adrenal gland cortex, right adrenal gland cortex |
Protein interactions among cohort
Intra-cohort edges: 2.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| APOE | 6,793 |
| FBLN5 | 2,301 |
| HMCN1 | 1,369 |
| CFHR1 | 599 |
| CFHR3 | 373 |
Intra-cohort edges
| A | B | Sources |
|---|---|---|
| CFHR1 | HMCN1 | string_interaction |
| CFHR3 | HMCN1 | string_interaction |
Structural data
PDB: 2 · AlphaFold-only: 3 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| APOE | P02649 | 29 |
| CFHR1 | Q03591 | 2 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| CFHR3 | Q02985 | 91.93 |
| FBLN5 | Q9UBX5 | 83.69 |
| HMCN1 | Q96RW7 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 37. Enrichment computed across 5 evidence-associated genes (4 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Regulation of Complement cascade | 2 | 116.5× | 0.004 | CFHR1, CFHR3 |
| Chylomicron clearance | 1 | 571.0× | 0.026 | APOE |
| Chylomicron assembly | 1 | 285.5× | 0.026 | APOE |
| Chylomicron remodeling | 1 | 285.5× | 0.026 | APOE |
| HDL remodeling | 1 | 285.5× | 0.026 | APOE |
| Plasma lipoprotein assembly | 1 | 178.4× | 0.028 | APOE |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 1 | 158.6× | 0.028 | APOE |
| Scavenging by Class A Receptors | 1 | 150.3× | 0.028 | APOE |
| Binding and Uptake of Ligands by Scavenger Receptors | 1 | 135.9× | 0.028 | APOE |
| Plasma lipoprotein remodeling | 1 | 119.0× | 0.028 | APOE |
| Plasma lipoprotein clearance | 1 | 119.0× | 0.028 | APOE |
| NR1H2 and NR1H3-mediated signaling | 1 | 98.5× | 0.028 | APOE |
| Metabolism of fat-soluble vitamins | 1 | 95.2× | 0.028 | APOE |
| Nuclear signaling by ERBB4 | 1 | 86.5× | 0.028 | APOE |
| Elastic fibre formation | 1 | 84.0× | 0.028 | FBLN5 |
| Molecules associated with elastic fibres | 1 | 77.2× | 0.028 | FBLN5 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 1 | 77.2× | 0.028 | APOE |
| Signaling by ERBB4 | 1 | 68.0× | 0.030 | APOE |
| Visual phototransduction | 1 | 64.9× | 0.030 | APOE |
| Retinoid metabolism and transport | 1 | 62.1× | 0.030 | APOE |
| Plasma lipoprotein assembly, remodeling, and clearance | 1 | 57.1× | 0.031 | APOE |
| Metabolism of vitamins and cofactors | 1 | 29.1× | 0.057 | APOE |
| Amyloid fiber formation | 1 | 25.7× | 0.058 | APOE |
| Signaling by Nuclear Receptors | 1 | 25.5× | 0.058 | APOE |
| Post-translational protein phosphorylation | 1 | 25.0× | 0.058 | APOE |
| Sensory Perception | 1 | 23.8× | 0.059 | APOE |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 1 | 21.6× | 0.062 | APOE |
| Signaling by Receptor Tyrosine Kinases | 1 | 12.9× | 0.099 | APOE |
| Vesicle-mediated transport | 1 | 8.7× | 0.140 | APOE |
| Transport of small molecules | 1 | 6.3× | 0.185 | APOE |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| complement activation | 2 | 249.7× | 0.003 | CFHR1, CFHR3 |
| lipid transport involved in lipid storage | 1 | 3370.4× | 0.005 | APOE |
| maintenance of location in cell | 1 | 3370.4× | 0.005 | APOE |
| intermediate-density lipoprotein particle clearance | 1 | 3370.4× | 0.005 | APOE |
| intramembranous bone growth | 1 | 3370.4× | 0.005 | FBLN5 |
| positive regulation of lipid transport across blood-brain barrier | 1 | 3370.4× | 0.005 | APOE |
| regulation of cellular response to very-low-density lipoprotein particle stimulus | 1 | 3370.4× | 0.005 | APOE |
| triglyceride-rich lipoprotein particle clearance | 1 | 1685.2× | 0.007 | APOE |
| regulation of amyloid-beta clearance | 1 | 1685.2× | 0.007 | APOE |
| regulation of amyloid fibril formation | 1 | 1685.2× | 0.007 | APOE |
| positive regulation of low-density lipoprotein particle receptor catabolic process | 1 | 1123.5× | 0.008 | APOE |
| negative regulation of triglyceride metabolic process | 1 | 842.6× | 0.008 | APOE |
| positive regulation of phospholipid efflux | 1 | 842.6× | 0.008 | APOE |
| regulation of behavioral fear response | 1 | 842.6× | 0.008 | APOE |
| very-low-density lipoprotein particle clearance | 1 | 674.1× | 0.008 | APOE |
| acylglycerol homeostasis | 1 | 674.1× | 0.008 | APOE |
| cellular response to lipoprotein particle stimulus | 1 | 674.1× | 0.008 | APOE |
| AMPA glutamate receptor clustering | 1 | 674.1× | 0.008 | APOE |
| NMDA glutamate receptor clustering | 1 | 674.1× | 0.008 | APOE |
| positive regulation of lipoprotein transport | 1 | 674.1× | 0.008 | APOE |
| positive regulation of dendritic spine maintenance | 1 | 674.1× | 0.008 | APOE |
| regulation of amyloid precursor protein catabolic process | 1 | 674.1× | 0.008 | APOE |
| positive regulation of amyloid fibril formation | 1 | 674.1× | 0.008 | APOE |
| chylomicron remnant clearance | 1 | 561.7× | 0.008 | APOE |
| lipoprotein biosynthetic process | 1 | 561.7× | 0.008 | APOE |
| regulation of removal of superoxide radicals | 1 | 561.7× | 0.008 | FBLN5 |
| high-density lipoprotein particle clearance | 1 | 481.5× | 0.008 | APOE |
| lipoprotein catabolic process | 1 | 481.5× | 0.008 | APOE |
| negative regulation of cholesterol biosynthetic process | 1 | 481.5× | 0.008 | APOE |
| very-low-density lipoprotein particle remodeling | 1 | 421.3× | 0.008 | APOE |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 5
Druggability breadth: 0 of 5 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| HMCN1 | 0 | 0 |
| CFHR1 | 0 | 0 |
| CFHR3 | 0 | 0 |
| FBLN5 | 0 | 0 |
| APOE | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 1 | CFHR1 |
| D | Druggable family + AlphaFold only, no drug | 2 | HMCN1, CFHR3 |
| E | Difficult family or no structure, no drug | 2 | FBLN5, APOE |
Undrugged target profiles
5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| HMCN1 | 0 | — |
| CFHR1 | 0 | — |
| CFHR3 | 0 | — |
| FBLN5 | 0 | — |
| APOE | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 14.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 8 |
| PHASE2 | 5 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07403825 | PHASE4 | RECRUITING | Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material |
| NCT06722157 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy |
| NCT02684578 | PHASE2 | COMPLETED | Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD |
| NCT03038880 | PHASE2 | COMPLETED | Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration |
| NCT03972709 | PHASE2 | TERMINATED | A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) |
| NCT04607148 | PHASE2 | TERMINATED | A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration |
| NCT06582511 | Not specified | ACTIVE_NOT_RECRUITING | Evaluating Metabolic Changes Induced by PhotoBioModulation Through Spectrally Resolved Autofluorescence in Dry Age-Related Macular Degeneration Patients |
| NCT03418220 | Not specified | COMPLETED | Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD) |
| NCT03794752 | Not specified | TERMINATED | Visual Enhancement Device in Low Vision Patients |
| NCT05593913 | Not specified | COMPLETED | Clinical Evaluation of VeriSee AMD in Screening for Age-Related Macular Degeneration |
| NCT05677685 | Not specified | COMPLETED | VISUPRIME® Eye Drops |
| NCT05961332 | Not specified | COMPLETED | COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy |
| NCT05988827 | Not specified | COMPLETED | Effect of Minimizing Light Exposure Intensity on Macular Function After Cataract Surgery in Patients With Early or Intermediate AMD |
| NCT07255885 | Not specified | COMPLETED | CRYSTALSIGHT: ‘‘Cohort 1.5 Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FARICIMAB | 4 | 1 |
| METFORMIN | 4 | 1 |
| PEGCETACOPLAN | 4 | 1 |
| GALEGENIMAB | 2 | 2 |